We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AMRI and Multispan Ink Collaboration Agreement
News

AMRI and Multispan Ink Collaboration Agreement

AMRI and Multispan Ink Collaboration Agreement
News

AMRI and Multispan Ink Collaboration Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AMRI and Multispan Ink Collaboration Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Albany Molecular Research Inc. has announced that it has signed a collaboration agreement with biotechnology company Multispan Inc. to co-market their G protein-coupled receptor (GPCR) drug discovery services to global pharmaceutical and biotechnology clients.

As part of the three-year agreement, AMRI gains access to Multispan's uniquely differentiated GPCR cell lines, assay capabilities and expertise. Multispan's customers will benefit from AMRI's global integrated drug discovery solutions, including high-throughput screening (HTS) and discovery medicinal chemistry.

"We are excited to be entering into this collaboration with Multispan as we implement our new U.S. integrated drug discovery center located on the Buffalo Niagara Medical Campus," said Rory Curtis, Ph.D., Vice President, Discovery Biology and Pharmacology, and Site Head of AMRI Buffalo. "As a biotechnology company that exclusively focuses on drug discovery research targeting GPCRs, Multispan has an impressive collection of human GPCR clones and GPCR-expressing cell lines for HTS, which will be beneficial to AMRI's integrated drug discovery efforts."

Aimed at increasing success in GPCR drug discovery, the alliance with Multispan is an example of the local and national partnerships AMRI is creating to combine validated assays and technologies with its HTS and analytic informatics.

"We have a responsibility to our partners and customers to use the best assays available to improve GPCR drug discovery, drive reductions in discovery cycle time and yield compounds that will ultimately be successful in the clinic," Dr. Curtis continued. "Our strategy is to leverage and build creative and effective collaborations with on-campus and off-campus partners from academia, biotech and Pharma."

"We are excited to bring our GPCR capabilities and services to AMRI's customers through this strategic alliance," added Helena Mancebo, CEO of Multispan. "In addition, we are eager for our customers to have access to the leading-edge capabilities for drug discovery that AMRI's new center in Buffalo offers across biology and medicinal chemistry."

Advertisement